Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
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
4NcVU1FPyAwYq0jE